Epoetin alfa biosimilar (Claris Lifesciences)

阿法依伯汀生物类似药 (Claris Lifesciences)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEpoetin alfa biosimilar (Claris Lifesciences)
Drug Alias Name阿法依伯汀生物仿制药 (Claris Lifesciences)Recombinant human erythropoietin (Claris Lifesciences)Epotin
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemiaPremature Birth
Global Approved IndicationsAnemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2011/01/01
Country/TerritoryUnited StatesIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesClaris Lifesciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesClaris Lifesciences Ltd
Inactive CompaniesUniversity Of Washington
Active IndicationsAnemia
Inactive IndicationsPremature Birth

Other Information

ATC CodeB03XA01
Related LinksN/A